Therapeutic implications of the gender-specific aspects of cardiovascular disease.
about
G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammationSex-based differences in cardiac ischaemic injury and protection: therapeutic implicationsLong-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progressionSex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes MellitusAcute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: a simulation studyA cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1α expression and mitochondrial biogenesisSex Differences in Clinical Features of Early, Treated Parkinson's Disease.Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.Chromosome Y variants from different inbred mouse strains are linked to differences in the morphologic and molecular responses of cardiac cells to postpubertal testosteroneLate onset of neutral lipid storage disease due to novel PNPLA2 mutations causing total loss of lipase activity in a patient with myopathy and slight cardiac involvement.GenderMedDB: an interactive database of sex and gender-specific medical literature.Analysis of sex and gender-specific research reveals a common increase in publications and marked differences between disciplines.Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction.PDE5 inhibitor efficacy is estrogen dependent in female heart disease.Sex/gender medicine. The biological basis for personalized care in cardiovascular medicine.Age and ovariectomy abolish beneficial effects of female sex on rat ventricular myocytes exposed to simulated ischemia and reperfusion17β-Estradiol-induced interaction of ERα with NPPA regulates gene expression in cardiomyocytes.Effects of estrogen, an ERα agonist and raloxifene on pressure overload induced cardiac hypertrophy.Sex differences in inflammation during atherosclerosis.Mitochondrial maintenance failure in aging and role of sexual dimorphism.Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesisRenal phenotype of ET-1 transgenic mice is modulated by androgensSex and gender differences in health. Science & Society Series on Sex and Science.Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity.In silico Prediction of Sex-Based Differences in Human Susceptibility to Cardiac Ventricular TachyarrhythmiasHEROD: a human ethnic and regional specific omics database.Gender differences in response to chronic treatment with 17β-oestradiol and 17β-aminoestrogen pentolame on hemostasis in rats.Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Reverse engineering gene networks to identify key drivers of complex disease phenotypes.Sex-specific pathways in early cardiac response to pressure overload in mice.Testosterone-derived estradiol production by male endothelium is robust and dependent on p450 aromatase via estrogen receptor alpha.Sexually dimorphic gene expression in the heart of mice and men.Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats.Stroke prevention in women: challenges and opportunitiesNative myocardial longitudinal (T1 ) relaxation time: Regional, age, and sex associations in the healthy adult heartOn the role of autophagy in human diseases: a gender perspective.Comparative differential proteomic profiles of nonfailing and failing hearts after in vivo thoracic aortic constriction in mice overexpressing FKBP12.6.Gender differences in cardiac ischemic injury and protection--experimental aspects.Heart failure in women: epidemiology, biology and treatment.Factors affecting the development of adverse drug reactions (Review article)The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG).
P2860
Q24307603-E9B362BB-40B1-47A3-A553-1A2F25A26118Q26996309-9FCDCBB7-569C-4A96-9E3D-DE345519381BQ28235380-36118C4A-225A-49B8-A273-E563E8B060FEQ28395801-7D7DF9E9-065B-4A3E-A2CD-CD3C5FFD7ED3Q28472692-FA1E3D22-3416-403B-ADF6-198409186721Q28484191-FD9ACDE6-5FAB-450E-A1AE-534483974C14Q30375563-AFD4CCB1-6C98-4ED1-B635-312E960DE8E4Q33347137-4D747F91-C06A-4CD3-81BA-F57FB8072F0AQ33427650-10113079-22D2-49B1-999F-B61BFBE335E4Q33656924-41AA2A7F-CAD7-4721-B54D-9CE332D12F69Q33716946-C709B36A-B19E-465E-871E-A897BA9AD8F2Q33743559-2158C385-51D7-4471-B5CC-0F7C94873485Q33803183-B8BA3505-1FDD-4786-89E1-003CB9D77D3FQ33872491-C03FB8EF-4201-4571-A610-C15CE301F53BQ34136187-5755AF85-B4AA-4FF5-B30B-79525EF5A36DQ34305431-48906F56-D3E3-41C8-82E5-2165264B0684Q34409624-7604E54B-6160-42E0-B27C-F282BC15AB59Q34507109-B65D315D-5A44-44D0-9FEF-A68B97825C8DQ35509492-C634606A-D153-46D6-9CBF-B2EBBD76459CQ35538600-21134B42-7FBA-4638-8102-89E947424FD2Q35868721-76C47413-6758-44C1-8306-412A21261297Q35959010-0BD86297-8E21-4553-A3B5-80567643C90AQ36073394-00DE7B89-AABB-48D7-838B-5D21F7FC788EQ36182975-4959627E-279C-4B54-B5C4-1244CEA5AE1AQ36234352-3E9DA5CE-28E3-4FEB-B2CF-925EA2E969AFQ36382897-B21DE7C4-A40F-4712-BAC1-234EB430A250Q36470216-9646C5F5-8A46-4B6D-882F-3536E337A62BQ36609005-66ABD168-A245-416B-B33E-EF794956B4D8Q36839065-77DF82F9-8C90-435D-AA85-F3FB3C0929ACQ36886122-E746B891-D144-4A47-99A6-4EA018AC68CFQ36890022-FAC6473F-78A6-41DE-8B12-3D3594484B80Q36948209-8A411EB0-7B9B-4C5B-BD96-7BFCB45CBFD0Q37080263-049E892E-6B87-4AEB-9CE3-2D7D5D280CE2Q37260713-137FA55C-3A8B-46FC-B606-FC2403967C31Q37295450-0F66F8F7-D938-4890-A9D5-62BCB576A3B4Q37328034-1F7111F8-FA13-42C4-A519-62397F5749E6Q37527487-38AD6293-1DC7-40C6-A5D5-F54A87663109Q37585303-D756D636-7EA4-49BB-AB0D-C65BB025C6C9Q37631543-C8E26055-857A-40C0-B15C-30FD5EC4548CQ37683747-5948C063-A20E-4ED9-94D2-BB944DF425A6
P2860
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@ast
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@en
type
label
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@ast
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@en
prefLabel
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@ast
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@en
P2860
P356
P1476
Therapeutic implications of the gender-specific aspects of cardiovascular disease.
@en
P2860
P2888
P304
P356
10.1038/NRD2032
P577
2006-05-01T00:00:00Z
P5875
P6179
1053312489